

RESEARCH ARTICLE

Deficiency in Galectin-3, -8, and -9 impairs immunity to chronic *Mycobacterium tuberculosis* infection but not acute infection with multiple intracellular pathogens

Huntly M. Morrison¹, Julia Craft², Rafael Rivera-Lugo¹, Jeffery R. Johnson^{3^{aa}}, Guillaume R. Golovkine^{1^{ab}}, Samantha L. Bell^{4^{ac}}, Claire E. Dodd¹, Erik Van Dis^{1^{ae}}, Wandy L. Beatty⁵, Shally R. Margolis^{1^{af}}, Teresa Repasy^{1^{ag}}, Isaac ShakerWriting – review & editing², Angus Y. Lee⁶, Russell E. Vance^{1,7}, Sarah A. Stanley^{1,8}, Robert O. Watson⁴, Nevan J. Krogan³, Daniel A. Portnoy¹, Bennett H. Penn^{2^{ax}}, Jeffery S. Cox^{1^{ax}}

1 Department of Molecular and Cell Biology, Division of Immunology and Molecular Medicine, University of California, Berkeley, Berkeley, California, United States of America, **2** Department of Internal Medicine, Division of Infectious Diseases, University of California, Davis, Davis, California, United States of America, **3** Department of Cellular and Molecular Pharmacology, University of California, San Francisco; Quantitative Biosciences Institute (QBI), University of California, San Francisco; Gladstone Institutes, San Francisco, California, United States of America, **4** Department of Microbial Pathogenesis and Immunology, Texas A&M Health, School of Medicine, Bryan, Texas, United States of America, **5** Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, United States of America, **6** Cancer Research Laboratory, University of California, Berkeley, Berkeley, California, United States of America, **7** Howard Hughes Medical Institute, University of California, Berkeley, Berkeley, California, United States of America, **8** School of Public Health, Division of Infectious Diseases and Vaccinology, University of California, Berkeley, Berkeley, California, United States of America

☯ These authors contributed equally to this work.

^{aa} Current address: Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America

^{ab} Current address: Evotec SAS, Toulouse, France

^{ac} Current address: Department of Microbiology, Biochemistry, and Molecular Genetics, New Jersey Medical School, Rutgers Biomedical Health Sciences, Rutgers University, Newark, New Jersey, United States of America

^{ad} Current address: Center for Emerging Pathogens, New Jersey Medical School, Rutgers Biomedical Health Sciences, Rutgers University, Newark, New Jersey, United States of America

^{ae} Current address: Departments of Immunology and Medicine, University of Washington, Seattle, Washington, United States of America

^{af} Current address: Department of Microbiology, University of Washington, Seattle, Washington, United States of America

^{ag} Current address: Bio-Rad Laboratories, Seattle, Washington, United States of America

* bhpenn@ucdavis.edu (BHP); jeff.cox@berkeley.edu (JSC)

Abstract

Macrophages employ an array of pattern recognition receptors to detect and eliminate intracellular pathogens that access the cytosol. The cytosolic carbohydrate sensors Galectin-3, -8, and -9 (Gal-3, Gal-8, and Gal-9) recognize damaged pathogen-containing phagosomes, and Gal-3 and Gal-8 are reported to restrict bacterial growth via autophagy in cultured cells. However, the contribution of these galectins to host resistance during bacterial infection in vivo remains unclear. We found that Gal-9 binds directly to *Mycobacterium tuberculosis* (*Mtb*) and *Salmonella enterica* serovar Typhimurium (*Stm*) and localizes to *Mtb* in macrophages. To determine the combined contribution of membrane damage-sensing galectins



OPEN ACCESS

Citation: Morrison HM, Craft J, Rivera-Lugo R, Johnson JR, Golovkine GR, Bell SL, et al. (2023) Deficiency in Galectin-3, -8, and -9 impairs immunity to chronic *Mycobacterium tuberculosis* infection but not acute infection with multiple intracellular pathogens. *PLoS Pathog* 19(6): e1011088. <https://doi.org/10.1371/journal.ppat.1011088>

Editor: Padmini Salgame, New Jersey Medical School, UNITED STATES

Received: December 28, 2022

Accepted: May 1, 2023

Published: June 23, 2023

Copyright: © 2023 Morrison et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All mass spectrometry data related to this manuscript are available in the Dryad Data Repository with the identifier DOI: <https://doi.org/10.6078/D1914X>. All other relevant data are within the manuscript and its Supplementary Information files.

Funding: This work was supported by funding from the National Institute of Health (R37 AI075039 to REV; P01 AI063302 to REV; P01

AI063302 to SAS; R01 AI27655 to DAP; P01 AI063302 to DAP; R01 AI144149-04 to BHP; P01 AI063302 to JSC). The funders played no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: REV is on the Scientific Advisory Board of Tempest Therapeutics, and is an Investigator of the Howard Hughes Medical Institute NJK has consulting agreements with the Icahn School of Medicine at Mount Sinai, New York, Maze Therapeutics, and Interline Therapeutics. He is a shareholder in Tenaya Therapeutics, Maze Therapeutics and Interline Therapeutics, and is financially compensated by GEN1E Lifesciences, Inc. and Twist Bioscience Corp. The Krogan Laboratory has received research support from Vir Biotechnology and F. Hoffmann-La Roche. DAP has a financial interest in Laguna Biotherapeutics and both he and the company stand to benefit from commercialization of the results of this research.

to immunity, we generated Gal-3, -8, and -9 triple knockout (TKO) mice. *Mtb* infection of primary macrophages from TKO mice resulted in defective autophagic flux but normal bacterial replication. Surprisingly, these mice had no discernable defect in resistance to acute infection with *Mtb*, *Stm* or *Listeria monocytogenes*, and had only modest impairments in bacterial growth restriction and CD4 T cell activation during chronic *Mtb* infection. Collectively, these findings indicate that while Gal-3, -8, and -9 respond to an array of intracellular pathogens, together these membrane damage-sensing galectins play a limited role in host resistance to bacterial infection.

Author summary

Intracellular bacterial pathogens cause many of the world's most deadly infectious diseases. A common requirement for nearly all intracellular pathogens is the ability to damage the endomembrane compartments in which they reside, which allows pathogens access to the nutrient-rich cytosol of the host. However, membrane damage also creates a "pattern of pathogenesis" that triggers antimicrobial immune responses. Galectin-3, -8, and -9 (Gal-3, Gal-8, and Gal-9) act as a surveillance system for membrane damage and Gal-3 and Gal-8 inhibit bacterial growth by activating autophagy, a cellular pathway that can capture cytosolic bacteria and degrade them in lysosomes. Membrane damage-sensing galectins were hypothesized to promote bacterial killing during acute infection yet their role in the immune response of an infected animal remains unclear. Here, we show that mice deficient for Gal-3, -8, and -9 had no defects in resistance to acute infection with the pathogens *Listeria monocytogenes*, *Salmonella enterica* serovar Typhimurium, and *Mycobacterium tuberculosis* (*Mtb*), and were only modestly susceptible to chronic *Mtb* infection. Our data suggest that Gal-3, -8 and -9 are not critical for innate immune responses during acute infection and may play a more prominent role in the adaptive immune response. These results broaden our understanding of the role of membrane damage-sensing pathways in host defense against bacterial infection.

Introduction

Infectious diseases caused by intracellular bacterial pathogens are among the leading causes of mortality worldwide [1]. Bacterial replication within host cells is critical for pathogenesis yet also exposes bacteria to a myriad of innate immune sensing mechanisms [2]. Detection of pathogen-associated molecular patterns (PAMPs) by pattern recognition receptors (PRRs) activates multiple cell-intrinsic antimicrobial pathways, including autophagy and inflammasome assembly [3, 4], and proinflammatory signaling pathways required for coordinating protective adaptive immune responses [5, 6]. However, the relative importance and precise function of distinct pathogen-sensing pathways during in vivo infection remains poorly understood.

Macrophages can sense and respond to intracellular pathogens using galectins [7–9], a family of soluble β -galactoside-binding receptors that facilitate carbohydrate sensing in diverse biological contexts, including chronic inflammation, autoimmunity, cancer, and infection [10–12]. There are fifteen galectins in mammals, each containing one or two carbohydrate-recognition domains (CRDs) [12]. While some galectins are reported to act extracellularly through an atypical secretion mechanism [10, 13], Galectin-3, -8, and -9 (Gal-3, Gal-8, and

Gal-9) act as cytoplasmic sensors for intracellular membrane damage by recognizing luminal glycolipids and glycoproteins that become exposed during endomembrane rupture [7, 9]. Lysosomal membrane damage activates Gal-3, -8, and -9, which promote repair and clearance of damaged lysosomes [14–18]. Several bacteria, including *Mycobacterium tuberculosis* (*Mtb*), *Salmonella enterica* serovar Typhimurium (*Stm*), *Listeria monocytogenes* (*Lm*), *Shigella flexneri*, and *Legionella pneumophila* (*Lp*), inflict phagosomal membrane damage that leads to the recruitment of Gal-3, -8, and -9 [7–9, 19–21]. Previously, we found that all three of these galectins are also ubiquitylated during *Mtb* infection [22, 23]. In addition to binding host carbohydrate, some galectins can interact directly with bacteria and their cell wall glycans [24–27], including Gal-9 binding of the *Mtb* cell wall polysaccharide arabinogalactan [27]. While galectins can promote proinflammatory signaling and recruitment of antibacterial guanylate-binding proteins during infection [21, 27], the primary mechanism by which they are proposed to promote cell-intrinsic bacterial killing is via activation of antibacterial autophagy [9, 15, 20].

Autophagy is a conserved process that targets, captures, and degrades cytosolic cargo, including intracellular pathogens [28, 29]. Autophagy is critical for defense against *Mtb* infection in mice and macrophages [30]. During macrophage infection, *Mtb*-mediated perforation of the phagosome via the bacterial ESX-1 secretion system promotes the recruitment of multiple autophagy-activating proteins [3, 15, 20, 31, 32]. Recruitment of the ubiquitin ligases Parkin and Smurf1 initiate autophagic targeting of cytosolic bacteria by ubiquitylating substrates around bacteria with K63- and K48-linked polyubiquitin chains [32, 33]. Several ubiquitin-binding autophagy receptors, including p62, Ndp52, Tax1bp1, Nbr1, and Optineurin decode these ubiquitin signals into autophagy signaling cascades that nucleate LC3-positive (LC3+) phagophore membranes around bacteria to form the autophagosome, which is trafficked to lysosomes for degradation [20, 22, 31, 34]. In addition to the ubiquitin-mediated autophagy pathway, galectins promote antibacterial autophagy via Gal-3-mediated recruitment of the ubiquitin ligase Trim16 [15], and Gal-8-mediated recruitment of the autophagy receptors NDP52 and Tax1bp1, which promote autophagic targeting of *Stm* and *Mtb*, respectively [9, 20].

While it is clear that Gal-3, -8, and -9 are able to sense and respond to damaged phagosomes, the contribution that these membrane damage-sensing galectins make to antibacterial immunity is less certain. Most prior studies that have explored the ability of galectins to restrict the growth of intracellular bacteria have used immortalized cell lines. In an early seminal study, it was shown that depletion of Gal-8 in HeLa cells led to increased *Stm* replication [9]. Subsequent studies have also shown that depletion of Gal-3 or knockout of Gal-8 in the macrophage-like RAW 264.7 cell line led to increased *Mtb* replication [15, 20]. However, only limited studies of galectin-deficient mice challenged with bacterial pathogens have been carried out. Mice deficient in either Gal-3 or Gal-8 subjected to a high-dose *Mtb* challenge succumbed slightly faster to *Mtb* infection [15, 16], although bacterial burden was not reported in either study. Mice deficient in Gal-9 challenged with high-dose intranasal *Mtb* showed a mild, two-fold increase in bacterial burden without any change in host survival reported [27]. Similarly, mice inoculated intravenously with Gal-9 knockout macrophages infected ex vivo with *Mtb* also showed a mild, two-fold increase in bacterial burden in comparison to wild-type (WT) control [13]. The potential for redundancy between these galectins, which all respond to endomembrane damage, could explain the seemingly mild phenotypes of individual galectin knockouts. Thus, the role of membrane damage-sensing galectins in host resistance to bacterial infection remains unclear.

In the present study, we identified Gal-9 in a mass spectrometry-based search for host proteins that bind to the surface of *Mtb*. We found that Gal-9 bound *Mtb* in a carbohydrate-dependent manner and, similar to Gal-3 and Gal-8, localized to bacteria in response to

phagosome damage during macrophage infection. To further characterize the collective role of membrane damage-sensing galectins *in vivo*, we generated Gal-3, -8, and -9 triple knockout (TKO) mice. Primary bone marrow-derived macrophages (BMMs) from TKO mice exhibited reduced autophagic flux yet maintained normal bacterial growth restriction during infection with multiple intracellular pathogens. Furthermore, TKO mice exhibited no defects in resistance to acute bacterial infection with *Mtb*, *Lm*, or *Stm*, and showed only modest susceptibility to chronic *Mtb* infection. These results suggest that membrane damage-sensing galectins play a limited role in antibacterial immunity *in vivo* and may fulfill roles other than mediating direct antibacterial resistance.

Results

Gal-9 binds to *Mtb*

To identify host proteins that bind to the *Mtb* surface, we performed pull-down experiments with formaldehyde-fixed *Mtb* incubated with lysates from differentiated THP-1 macrophages (Fig 1A). After washing the bacteria, the bound proteins were eluted with 8M urea and analyzed by liquid-chromatography mass spectrometry (LC-MS/MS) (Fig 1A), which identified ~300 human proteins (Tab A in S1 Table). We ranked the identified proteins using the Contaminant Repository for Affinity Purification (Tab B in S1 Table) [35], which identifies common contaminants in published pull-down experiments. We then focused on lipid- and carbohydrate-binding proteins, as these molecules are likely to recognize cell wall components during infection, and noted the presence of Gal-1 and Gal-9. Gal-1 is often an LC-MS/MS contaminant, whereas Gal-9 is predicted to be specific (Tab B in S1 Table) [35]. Since prior studies




Fig 1. Gal-9 binds and recruits to *Mtb*. (A) Experimental design for *Mtb* pull-down mass spectrometry identification of *Mtb*-binding proteins. (B) Domain organization of Gal-9. CRD, carbohydrate recognition domain. (C) Immunoblot of *in vitro* binding reactions between indicated pathogens and Gal-9-FLAG THP-1 lysate, probed with anti-FLAG antibody; IN, input; *Lm*, *Listeria monocytogenes*; *Stm*, *Salmonella enteria* serovar Typhimurium; *Cn*, *Cryptococcus neoformans*; *Mtb*, *Mycobacterium tuberculosis*. (D) Confocal microscopy of WT BMMs infected with WT or $\Delta eccC$ *Mtb*-GFP (MOI = 2) 8 hours post-infection and immunostained for endogenous Gal-9 and Gal-3. (E) Quantification of *Mtb*-GFP colocalization with Gal-9 or Gal-3 at indicated time points. Figures represent two independent experiments (D, E). An average of 882 cells were analyzed per technical replicate (D, E). Error bars represent SD from 3 technical replicates. The schematic was created with BioRender.com.

<https://doi.org/10.1371/journal.ppat.1011088.g001>

have shown that Gal-1 does not localize to bacterial phagosomes or appear to play a role in pathogen sensing [9, 20], we focused on Gal-9 (Fig 1B). To biochemically validate the LC-MS/MS results, we expressed FLAG-tagged mouse Gal-9 in RAW 264.7 mouse macrophages and performed similar pull-down experiments with formaldehyde-fixed *Mtb* as described above, followed by anti-FLAG immunoblotting. Consistent with our findings with human Gal-9 from THP-1 macrophages, mouse Gal-9 also bound to the surface of *Mtb* (Fig 1C). This interaction was dependent upon carbohydrate binding, as addition of lactose to the in vitro binding reaction blocked Gal-9 binding (Fig 1C). We used pull-down assays to further explore whether Gal-9 binds to other phylogenetically diverse intracellular pathogens and found that Gal-9 bound to *Stm* and did not bind to *Lm* or the fungal pathogen *Cryptococcus neoformans* (*Cn*) under the tested conditions (Fig 1C).

To determine whether Gal-9 localizes to *Mtb* in infected macrophages, we analyzed *Mtb*-infected Gal-9-FLAG cells using immunogold electron microscopy with anti-FLAG antibody (S1 Fig). Gal-9-FLAG was found primarily on extra-phagosomal membranes throughout the macrophage cytoplasm, with roughly 20% of puncta localized to phagosomal membranes and ~5% localizing to bacteria (S1 Fig). Taken together, these results demonstrate that Gal-9 can bind directly to *Mtb* via carbohydrate-binding and that Gal-9 localizes to *Mtb* in an infected macrophage.

Gal-9 recruitment to *Mtb* is ESX-1-dependent

To determine whether ESX-1-mediated membrane damage is required for the recruitment of endogenous Gal-9, we infected BMMs with fluorescent *Mtb* and used automated confocal microscopy to quantify Gal-9 recruitment to bacteria. *Mtb*-Gal-9 colocalization was evident as early as 3 hours post-infection and reached a maximum of 15% at 8 hours post-infection before returning to 10–12% at later times (Fig 1D and 1E). We observed minimal colocalization between Gal-9 and the ESX-1 secretion mutant $\Delta eccC$, indicating that Gal-9 recruitment requires ESX-1-mediated membrane damage and cytosolic access. As a comparison, we also measured endogenous Gal-3 recruitment to *Mtb* and found that Gal-3 similarly colocalized with approximately 8–11% of WT *Mtb* but showed no recruitment to $\Delta eccC$ *Mtb* (Fig 1D and 1E). Thus, endogenous Gal-9 is recruited to *Mtb* in an ESX-1-dependent manner soon after infection and maintains steady localization with a subpopulation of bacteria throughout infection.

Generation and validation of Gal-3, -8, and -9 triple knockout (TKO) mice

While many cell-intrinsic roles have been described for Gal-3, -8, and -9, their contributions to host immunity are incompletely understood. Prior studies have shown that Gal-3, -8, and -9 each make partial contributions to *Mtb* immunity in animal models [15, 16, 27]. Because the mild phenotypes of individual galectin knockouts could be due to functional redundancy between damage-responsive galectins, we sought to test the combined role of all three membrane damage-sensing galectins in antibacterial immunity in vivo by generating Gal-3, -8, and -9 triple knockout (TKO) mice. Using CRISPR/Cas9 genome editing, we generated two independent TKO mouse strains (strain 1 and strain 2), both containing frameshift mutations in each of the three galectins that result in premature stop codons. Western blotting of BMMs from both TKO strains confirmed that these mutations led to loss of protein expression (Figs 2A and S2A). Gal-3, -8, and -9 have documented roles in the response to lysosomal damage, which entail activation of lysophagy and ESCRT-mediated repair [15–18]. To determine whether TKO cells have defective lysophagy induction, we treated WT and TKO BMMs with the lysosomal damaging agent Leu-Leu-OMe (LLOMe) and quantified LC3 puncta. There was a modest yet statistically significant reduction in LC3 puncta per cell in TKO BMMs treated




Fig 2. TKO macrophages exhibit reduced autophagic flux. (A) Immunoblots of bone marrow-derived macrophage lysates from WT and TKO mice (strain 1) probed for indicated proteins. (B) Confocal microscopy of WT or TKO BMMs infected with *Mtb*-GFP (MOI = 2) 8 hours post-infection and immunostained for polyubiquitin. (C) Quantification of (B) for WT or $\Delta eccC$ *Mtb*-GFP colocalization with polyubiquitin. (D) Quantification of *Mtb*-GFP colocalization with polyubiquitin in WT or TKO BMMs at indicated time points. (E) Same as in (B) but stained with LysoTracker. (F) Quantification of (E) for WT or $\Delta eccC$ *Mtb* colocalization with LysoTracker signal. (G) Confocal microscopy of WT, TKO, *Atg5^{fl/fl} LysMcre^{-/-}*, or *Atg5^{fl/fl} LysMcre^{+/-}* BMMs infected with *Mtb*-GFP (MOI = 2) 8 hours post-infection and immunostained for LC3. (H) Quantification of (G) for *Mtb*-GFP colocalization with LC3. (I) Quantification of *Mtb*-LC3 colocalization in WT or TKO BMMs infected with *Mtb*-GFP (MOI = 2) 8 hours post-infection and treated with indicated concentrations of bafilomycin A1 for 3 hours prior to fixation. Figures represent two (D), or are representative of two (I), or four (B, C, E-H) independent experiments. An average of 2115 (B, C), 933 (D), 925 (E, F), 1464 (G, H), and 1636 (I) cells were analyzed per technical replicate. Error bars represent SD from three (G-I) or four (B-F) technical replicates, and * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$ by unpaired t-test.

<https://doi.org/10.1371/journal.ppat.1011088.g002>

with LLOMe (S2B and S2C Fig), indicating an impairment in damage-induced LC3 puncta formation and lysophagy in galectin-deficient cells. Thus, we have established a genetic system to evaluate the collective roles of membrane damage-sensing galectins in vivo.

Deficiency in Gal-3, -8, and -9 leads to reduced autophagic flux and accumulation of autophagy targeting intermediates

Given the characterized roles of Gal-3 and Gal-8 in antibacterial autophagy induction [9, 15, 20], we tested whether TKO macrophages were impaired for *Mtb*-targeted autophagy, which is characterized by recruitment of polyubiquitin chains and ubiquitin-binding autophagy receptors to cytosolic *Mtb* [31, 32]. We used automated confocal microscopy to quantify the recruitment of polyubiquitin, polyubiquitin linkage subtypes K48 and K63, and p62 to *Mtb* in both WT and TKO BMMs. We hypothesized that decreased *Mtb*-ubiquitin colocalization would indicate an impairment of autophagy initiation, whereas an increase would indicate either a block in *Mtb* delivery to the lysosome or a defect in phagosome repair, which could expose bacteria to increased autophagy targeting. TKO macrophages exhibited a 40–70% increase in *Mtb* colocalization with all autophagy markers tested (Figs 2B, 2C, S3A, and S3B). The increase in *Mtb*-ubiquitin colocalization persisted from 3 to 24 hours post-infection (Fig 2D). Both mock- and *Mtb*-infected WT and TKO cells had equivalent numbers of ubiquitin puncta (S3E Fig), suggesting that the increase in *Mtb*-ubiquitin colocalization in TKO cells is not due to accumulation of ubiquitin structures at baseline. As expected, the increase in ubiquitin-labeled bacteria was dependent upon ESX-1-mediated phagosome permeabilization (Fig 2B and 2C). We also measured *Mtb* colocalization with Tax1bp1 and Optineurin, which are autophagy receptors implicated in *Mtb*-targeted autophagy [20, 22, 31]. In contrast to p62, there were no differences in Tax1bp1 and Optineurin recruitment to *Mtb* between WT and TKO macrophages (S3C and S3D Fig), suggesting that galectins function downstream of p62 recruitment but do not affect targeting of Tax1bp1 or Optineurin.

To assess if autophagosome maturation was impaired, we measured *Mtb* delivery to the lysosome by infecting cells with *Mtb* and staining with LysoTracker. TKO macrophages showed a ~15% decrease in *Mtb*-LysoTracker colocalization relative to WT (Fig 2E and 2F). This loss in colocalization was not due to reduced LysoTracker staining from defects in lysosomal homeostasis or repair in TKO cells, as both mock- or *Mtb*-infected WT or TKO macrophages had similar numbers of LysoTracker puncta (S3F Fig), indicating that TKO cells maintain lysosomal integrity at baseline and during infection. In contrast to WT *Mtb*, infection with Δ eccC *Mtb* resulted in similar levels of *Mtb*-LysoTracker colocalization in WT and TKO cells (Fig 2E and 2F), indicating that galectin-dependent lysosomal trafficking requires ESX-1 and cytosolic access. We initially hypothesized that the reduction in *Mtb* lysosomal delivery in TKO cells might be due to defects in LC3+ phagophore recruitment to bacteria. However, LC3 immunostaining revealed no differences in steady-state *Mtb*-LC3 colocalization between WT and TKO BMMs during infection (Figs 2G, 2H, and S3G), while BMMs depleted of the core autophagy gene *Atg5* expectedly showed marked reduction in *Mtb*-LC3 colocalization relative to control. As expected, ESX1 mutants elicited minimal colocalization with LC3 (Fig 2G and 2H) [31]. Although we detected no difference in *Mtb*-LC3 colocalization, the reduction in *Mtb* lysosomal delivery in TKO cells suggested that autophagic flux was disrupted. To test this, we inhibited autophagosome degradation in the lysosome by treating infected cells with bafilomycin A1 and measured accumulation of LC3+ *Mtb* autophagosomes. TKO BMMs had a 50% reduction in accumulated LC3+ *Mtb* after treatment with bafilomycin A1 (Fig 2I), indicating that galectin deficiency leads to reduced autophagic flux of LC3+ *Mtb*. Taken together, these data suggest that while Gal-3, -8, and -9 are dispensable for ubiquitin and p62 recruitment, they function to promote autophagic flux and efficient delivery of cytosolic *Mtb* to the lysosome.

Gal-3, -8, and -9 are not required for control of intracellular bacterial pathogens in primary macrophages

We next tested whether membrane damage sensing galectins were important for cell-intrinsic restriction of bacterial growth. Our initial finding that human Gal-9 could bind directly to *Mtb* motivated us to evaluate its role in bacterial control during infection of human cells. To this end, we generated two different Gal-9 shRNA-knockdown THP-1 cells lines, infected them, and measured bacterial growth of a bioluminescent *Mtb* reporter strain (*Mtb*-LUX) [36]. Gal-9 knockdown cells exhibited normal bacterial control during infection (S4A Fig). We then took a genetic approach and used CRISPR/Cas9 to knockout Gal-9 in the RAW 264.7 mouse macrophage cell line. Interestingly, Gal-9^{-/-} cells were more permissive for *Mtb* replication, whereas knockout of Gal-3 yielded no differences (S4B Fig). Previous reports have also demonstrated antimicrobial roles for certain galectins in immortalized cell lines [9, 15, 20], but galectins have never been evaluated for restriction of *Mtb* growth in primary cells. Therefore, we further evaluated Gal-9 by measuring *Mtb* growth in Gal-9^{-/-} BMMs but observed no defects in bacterial control (S4C Fig). Similarly, we found that Gal-8, which was previously reported to promote bacterial control in immortalized cell lines [20], was not required for *Mtb* growth restriction in primary macrophages (S4D Fig). Taken together, these data indicate that although Gal-8 or Gal-9 can promote bacterial growth restriction in certain cell lines, they are dispensable for restriction of *Mtb* growth in primary macrophages.

We speculated that galectin single knockout BMMs exhibit normal bacterial control due to functional redundancy between membrane damage-associated galectins. To test this, we evaluated whether TKO BMMs were more permissive for *Mtb* replication. We found that despite defects in autophagic flux in TKO macrophages, bacterial growth kinetics were nearly identical between WT and TKO macrophages (Fig 3A and 3B), a finding we confirmed in separate experiments by directly enumerating *Mtb* colony-forming units (CFUs) (Fig 3C). In addition, TKO macrophages exhibited normal interferon-gamma (IFN- γ) dependent restriction of *Mtb* (Fig 3A). Thus, despite previously described roles for Gal-3, -8, and -9 in autophagy and restriction of bacterial growth in immortalized cell lines [9, 15, 20], we found no defects in cell-intrinsic *Mtb* restriction in the absence of all three membrane damage-sensing galectins.

The inability of Gal-3, -8, and -9 to restrict *Mtb* growth led us to examine whether other intracellular bacterial pathogens are restricted by the membrane damage-sensing galectins. We performed infections with *Stm*, *Lm*, or *Legionella pneumophila* (*Lp*), and found that TKO macrophages also exhibited normal restriction of bacterial growth with these pathogens (Fig 3D–3F). TKO macrophages additionally showed no defects in IFN- γ -dependent restriction of *Stm* (Fig 3D). Furthermore, negligible differences were found between WT and TKO macrophages infected with Δ *flaA* *Lp* (Fig 3E), which does not activate the NAIP5-NLRC4 inflammasome [37], or an autophagy-sensitive *Lm* strain (Δ *actA* PlcA^{H86A} PlcB^{H69G}, Fig 3F) [38], indicating that Gal-3, -8, and -9 are dispensable for inflammasome-independent immunity to *Lp* and *Lm*-targeted autophagy. Thus, across an array of conditions in both resting and activated primary macrophages, we found that Gal-3, -8, and -9 are not required for restricting the growth of several intracellular bacterial pathogens.

TKO mice exhibit partial impairment in host resistance to chronic *Mtb* infection

To assess the role of Gal-3, -8, and -9 during *Mtb* in vivo infection, TKO and WT mice were infected with aerosolized *Mtb* (Figs 4, S5, and S6). During the initial 21 days of infection, when innate immunity predominates, there were no differences in bacterial burden in TKO mice compared to WT (Fig 4A and 4B). During chronic infection, at 9 weeks post-infection, there




Fig 3. Gal-3, -8, and -9 are not required for bacterial growth restriction in primary macrophages. (A and B) Relative light units (RLU) fold change of WT or TKO BMMs infected with *Mtb*-LUX (MOI = 1, A; MOI = 5, B). (C) Colony-forming unit (CFU) fold change of WT or TKO BMMs infected with WT *Mtb* (MOI = 2). (D) CFU-fold change of WT or TKO BMMs infected with WT *Stm* (MOI = 10). (E) RLU of WT or TKO BMMs infected with WT or $\Delta flaA$ *Lp*-LUX (MOI = 0.01). (F) CFU per coverslip of WT or TKO BMMs infected with WT or $\Delta actA$ *PlcA*^{H86A} *PlcB*^{H69G} *Lm* (MOI = 0.25). Figures represent one (B, E), or two (F, A) independent experiments, or are representative of two (C, D) independent experiments. Error bars represent SD from three (D, F), four (A-C), or five (E) technical replicates, and * $p < 0.05$, ** $p < 0.01$: compared to WT BMM + WT bacteria (A, B, E), # $p < 0.05$, ## $p < 0.01$, ### $p < 0.0001$: compared to WT BMM + mutant bacteria (E, F). p -values determined by unpaired t-test.

<https://doi.org/10.1371/journal.ppat.1011088.g003>




Fig 4. TKO mice exhibit modestly impaired resistance to chronic *Mtb* infection. (A) WT and TKO female mice were aerosol infected with ~ 75 CFUs of *Mtb* Erdman and bacterial loads in lungs were enumerated by plating for CFU at indicated time points. CFU-fold change (relative to day 0 inoculum) from two pooled experiments is shown. $n = 10$ – 12 mice per genotype. (B) Same as in (A) but bacterial loads in spleens. (C) Survival of aerosol-infected mice. $n = 12$ – 13 mice per genotype. Figures represent one experiment (C) or represent data from two independent experiments (A, B). Bars in (A) and (B) represent the mean, error bars in (A) and (B) represent SEM, and p -values were determined by unpaired t-test (A, B), or Mantel-Cox log (C).

<https://doi.org/10.1371/journal.ppat.1011088.g004>

was a slight 2-3-fold increase in bacterial burden in the lungs of TKO mice in two independent experiments (S5 Fig). Although this effect did not meet a $p = 0.05$ threshold for statistical significance for each experiment, pooling the CFU-fold change data from both experiments showed a statistically significant effect (Fig 4A). TKO spleens also exhibited a trend towards higher bacterial burden at this time point (Fig 4B). In addition, TKO mice succumbed slightly faster to infection than WT mice (Fig 4C). To evaluate whether these changes were dependent on inoculum size, we infected mice with a higher bacterial load (~450 CFUs) and observed a similar trend toward slightly increased bacterial burdens in the lungs and spleens of TKO mice (S6 Fig). Taken together, these data show that mice deficient for Gal-3, -8, and -9 have no discernable defect in immunity to *Mtb* during the early acute phase of infection and have only modest defects in host resistance to chronic *Mtb* infection.

Deficiency in Gal-3, -8, and -9 leads to a specific defect in splenic Ag85B-specific T cell responses

Because TKO mice exhibited resistance defects exclusively during chronic infection, when T cell-mediated immunity promotes bacterial control, we assessed whether Gal-3, -8, and -9 could play a role in shaping the adaptive immune response. To this end, we performed IFN- γ enzyme-linked immunospot (ELISpot) assays to enumerate *Mtb*-specific T cells in both WT and TKO mice infected with *Mtb*. Splenocytes were isolated 21 days post-infection when bacterial CFU in WT and TKO animals were equivalent, and ELISpot was performed with the immunodominant I-A^b epitopes from *Mtb* antigens ESAT-6 and Ag85B (S7 Fig). Consistent with a contribution to adaptive immunity, we detected a reduction in IFN- γ -secreting Ag85B-specific T cells in TKO spleens harvested three weeks post-infection (S7A Fig). This difference seemed selective, as there were no differences in the number of IFN- γ -secreting ESAT-6-specific T cells (S7A Fig). We also measured T cell responses in the lung at this time point but found no differences between WT and TKO mice for either antigen (S7B Fig), possibly reflecting the robust enrichment of highly activated T cells in this organ [39, 40]. Finally, we measured splenic T cell responses in a high-dose infection and, in contrast to our low-dose infection results, observed no differences in Ag85B-specific T cell responses (S7C Fig), suggesting that *Mtb* infection can promote robust T cell activation in the absence of Gal-3, -8, and -9 if sufficient antigen is present. These findings suggest that membrane damage-sensing galectins promote full activation of CD4 T cells in some physiologic contexts, but not universally.

TKO mice exhibit normal resistance to infection with *Lm* or *Stm*

Given the surprisingly mild immune defects in response to *Mtb*, we broadened our analysis and challenged WT and TKO mice with *Lm* or *Stm*. Using a *Lm* intravenous infection model, we detected similar bacterial burdens in spleen and liver from WT and TKO mice at 48 hours post-infection (Fig 5A and 5B). Likewise, bacterial burdens were unaltered in TKO mice infected with *Stm* via the intraperitoneal route (Fig 5C and 5D). Thus, despite their well-established role in membrane damage-sensing and our data demonstrating direct pathogen recognition, simultaneous loss of all three phagosome-localized galectins has no discernable impact on the ability of the host to restrict several phylogenetically-diverse bacterial pathogens during the acute phase of infection and results in only modest impairments to host immunity during chronic *Mtb* infection.

Discussion

Given the previous work that demonstrated roles for galectins in antibacterial autophagy and bacterial control [9, 15, 20], we were surprised that mice lacking Gal-3, -8, and -9 had no




Fig 5. TKO mice exhibit normal bacterial control during infection with *Lm* or *Stm*. (A) WT and TKO mice were intravenously infected with 1×10^5 CFUs of *Lm* and bacterial loads in spleens were enumerated by plating for CFU at 48 hours post-infection. $n = 5$ mice per genotype. (B) Same as in (A) but bacterial loads in livers. (C) WT and TKO mice were infected via the intraperitoneal route with 1000 CFUs of *Stm* and bacterial loads in spleens were enumerated by plating for CFU at 24 hours post-infection. $n = 5$ mice per genotype. (D) Same as in (C) but bacterial loads in livers. $n = 4$ –5 mice per genotype. Figures represent data from one experiment (A, B), or are representative of three independent experiments (C, D). Bars represent the mean, error bars represent SEM, and p-values were determined by unpaired t-test.

<https://doi.org/10.1371/journal.ppat.1011088.g005>

resistance defects during the acute stage of infection with *Stm*, *Lm*, or *Mtb*. The absence of a significant immune deficit in TKO mice also stands in contrast to the clear resistance defects seen in autophagy-deficient animals during *Mtb* infection [30]. There are several possible explanations for the seemingly minimal contribution of Gal-3, -8, and -9 to antibacterial immunity during acute infection. First, redundancy in galectin function (e.g. different galectins or other pathways) may be compensating for Gal-3, -8, and -9 deficiency, although no other galectins are currently known to be targeted to damaged membranes. Alternatively, as several intracellular pathogens actively inhibit autophagy using specific virulence factors [41–43], these pathogens may inactivate galectins or downstream autophagy steps as a virulence strategy. Finally, it is possible that galectins play roles in cell types other than macrophages or in different physiologic contexts, such as mucosal immunity in the gut, where epithelial cells rather than professional phagocytes are the initial line of defense against an array of pathogens. Autophagy plays a protective role in the gut epithelium [44], and certain innate immune mechanisms are only evident during infection of the gut epithelium, exemplified by NOD2-mediated restriction of *Lm* growth during oral but not intravenous infection [45]. Thus, galectins may still have an important antibacterial role in other physiologic contexts beyond those we have tested here.

We found that TKO mice exhibited modest defects in bacterial control and survival during the chronic phase of *Mtb* infection and these findings are supported by previous *Mtb* studies using galectin single knockout mice and autophagy-related mouse models [15, 16, 27, 33]. In previous survival experiments, Gal-3^{-/-} and Gal-8^{-/-} mice exhibited mild defects in susceptibility to chronic *Mtb* infection following high dose aerosol challenge (200–3000 CFUs) [15, 16]. Similarly, Gal-9^{-/-} mice infected intranasally with an extremely high dose of *Mtb* (2×10^6 CFUs) had a modest two-fold increase in lung bacterial burden [27]. While there are many differences between these studies and ours (e.g. animal housing conditions, animal microbiota, *Mtb* strain and dose, and/or infection route), these data are in general agreement with our finding that membrane damage-associated galectins play a limited role in vivo during *Mtb* infection. The increased susceptibility of TKO mice during the chronic phase is also similar to mice that lack the autophagy-related ubiquitin ligase Smurf1, which also have higher *Mtb* burdens exclusively during the chronic phase and exhibit a very similar survival phenotype [33]. Whether the susceptibility of TKO mice is due to defects in direct antimicrobial killing or

aberrant inflammatory responses is currently unknown [33, 46, 47]. However, defects in host resistance during the chronic phase in both galectin-deficient mice and *Smurf1*^{-/-} mice may suggest that full and sustained activation of the autophagy pathway is important for long-term containment of *Mtb*.

Previous reports demonstrated that Gal-3 and Gal-8 promote restriction of bacterial growth in immortalized cell lines [9, 15, 20]. Similarly, we found that loss of Gal-9 in RAW 264.7 cells also resulted in increased *Mtb* replication. In contrast, when studying primary immune cells, we found that individual loss of Gal-8 or Gal-9 in BMMs resulted in no discernable change in intracellular *Mtb* replication. Furthermore, TKO BMMs lacking all membrane damage-sensing galectins exhibited normal restriction of *Mtb*, as well as *Stm*, *Lm*, and *Lp*. Taken together, this suggests that while membrane damage-sensing galectins have the potential to restrict bacterial growth in cell lines, there may be key differences between these cells and primary macrophages that account for the differential requirements for galectin activity to restrict bacterial growth. Indeed, previous reports have identified significant differences in the phagosome proteome, proteolytic capacity, and kinetics of lysosomal trafficking and proinflammatory signaling between primary BMMs and immortalized RAW 264.7 macrophages that may impact the role galectins play in antibacterial immunity [48, 49].

Our results showed that TKO macrophages exhibit impaired autophagic flux of LC3+ *Mtb* and slightly reduced *Mtb* lysosomal delivery. TKO cells also showed increased levels of ubiquitin+ and p62+ *Mtb* during infection, suggesting that Gal-3, -8, and -9 function downstream of ubiquitin and p62. However, *Mtb* association with the autophagy receptors Tax1bp1 and Optineurin were unchanged in TKO cells. Although a mechanistic understanding awaits further investigation, these observations suggest that there are different subsets of targeted phagosomes and that galectins play a role in promoting maturation of certain phagosomes. NDP52 also promotes autophagy via Gal-8 binding in human cells [9], however murine Ndp52 lacks the C-terminal ubiquitin- and Gal-8-binding regions and therefore is likely not to play in mouse cells [20, 50]. Of note, we do not see complete loss of autophagy in TKO cells, likely because numerous autophagy-promoting pathways are activated during *Mtb* infection [3, 31–33]. Indeed, robust ubiquitin recruitment to *Mtb* occurs in TKO macrophages, suggesting that ubiquitin-mediated autophagy pathways, promoted via Parkin, Smurf1, Trim16, or cGAS/Sting [15, 31–33], are largely intact in TKO macrophages and may partially compensate for defects in galectin-driven autophagy.

Our finding that galectin deficiency leads to slight impairments in both autophagy and antigen-specific CD4 T cell activation raises the possibility that these phenotypes could be linked and suggests how an autophagy phenotype might manifest during later stages of infection. Autophagy mediates the capture and degradation of cytosolic pathogens and antigens, after which the peptide constituents are trafficked to MHC-class-II-containing late endosomes and then loaded onto MHC class II complexes for presentation to CD4 T cells [51–54]. During *Mtb* infection, inhibition of autophagy was shown to impair Ag85B-specific, but not ESAT-6-specific CD4 T cell activation [55], possibly suggesting that some microbial antigens, but not others, require autophagy for efficient antigen presentation. Similarly, the CD4 T cell activation defect we observed in TKO mice was specific to Ag85B, while ESAT-6-specific CD4 T cell responses were unchanged. How some antigens, but not others, might access MHC class II compartments via autophagy remains unknown. It is possible that highly expressed and secreted antigens, like ESAT-6 [56], do not require autophagy for antigen presentation and instead access the antigen presentation pathway via phagocytosis and endolysosomal trafficking. In contrast, Ag85B, a cell wall antigen that is downregulated at three weeks post-infection and exhibits low abundance during chronic infection [57, 58], might rely on autophagy for efficient antigen presentation.

Although we and Wu et al. found that Gal-9 can bind directly to the surface of *Mtb* [27], the ligands recognized by Gal-9 during infection remain unclear. The mycobacterial cell wall, from inside to out, is comprised of an inner membrane, a layer of peptidoglycan covalently linked to a subsequent layer of arabinogalactan (AG), an extremely hydrophobic and relatively-impermeant outer membrane (OM) consisting mainly of long-chain mycolic acids, and a loosely associated polysaccharide “capsule” at the very surface [59, 60]. Wu et al. reported that Gal-9 recognized *Mtb* AG [27], though this layer is internal to the OM and unlikely to be accessible to Gal-9 in healthy, dividing bacteria [60]. A possible solution to this conundrum is that permeabilization of the outermost capsule and mycolic acid layer in vivo (or with detergents routinely used in mycobacterial growth medium) [59], might expose AG to Gal-9. Moreover, it is possible that Gal-9 primarily recognizes dead or dying bacteria that have already been damaged during infection in order to clear bacterial corpses (and their PRR-activating ligands) from the cytosol via autophagy. Gal-9 localizes to damaged endosomes and lysosomes independently of bacterial infection [9, 18], indicating that Gal-9 also recognizes an endogenous carbohydrate ligand. In line with this, our immuno-EM studies showed that most Gal-9 colocalizes with host membranes, while a small fraction colocalizes with *Mtb* in infected macrophages. Recognition of host glycoproteins on damaged membranes or release of AG or other Gal-9 bacterial ligands could localize Gal-9 to extra-phagosomal compartments [61]. Lastly, our observation that Gal-9 also binds *Stm* but not *Lm* suggests Gal-9 recognition of bacterial constituents is not limited to AG and is selective for a subset of bacteria. Indeed, other galectin-bacteria interactions have been identified, including Gal-3/Gal-9-*Leishmania major*, Gal-4/Gal-8-*Escherichia coli*, and Gal-3-*Neisseria meningitidis* [24–26]. This suggests a scenario where galectins have divergent binding preferences, allowing the recognition of a broader array of microbes.

In conclusion, our data suggest that although Gal-3, -8, and -9 contribute to autophagy in macrophages, they play a limited role in the immune response to systemic bacterial infection. These membrane damage-sensing galectins had no discernable impact on acute infection with *Mtb*, *Stm*, or *Lm* in vivo, and had a modest effect on host resistance to chronic *Mtb* infection. These data suggest that the role of Gal-3, -8, and -9 in antibacterial immunity is not generalized, but rather is limited to specific physiologic contexts in vivo.

Methods

Ethics statement

Mouse use and procedures were approved by the Office of Laboratory and Animal Care at the University of California, Berkeley (protocol AUP-2015-11-8096), and University of California, Davis (protocol #22365) in adherence with federal guidelines from the *Guide for the Care and Use of Laboratory Animals* of the National Institute of Health.

Dryad DOI

<https://doi.org/doi:10.6078/D1914X> [69].

Pathogen pull-down for mass spectrometry and immunoblotting

For *Mtb* pull-down mass spectrometry, *Mtb* was fixed in PBS with 4% PFA, washed three times with PBS, and pelleted. 50 μ L of *Mtb* pellet was incubated for 3 hours with 1 mL of 10 mg/mL differentiated THP-1 lysate, washed four times with PBS, and eluted in 8M urea with Rapigest (Waters) before LC-MS sample preparation. For *Mtb*, *Lm*, *Stm*, and *Cn* pull-down for Gal-9-FLAG immunoblotting, pathogens were fixed, washed, and pelleted as described above.

1 mL of 10 mg/mL RAW 264.7 Gal-9-FLAG lysate was incubated, washed, and eluted as described above prior to immunoblotting.

Mass spectrometry

Samples were denatured and reduced in 2 M urea, 10 mM NH_4HCO_3 , 2 mM DTT for 30 minutes at 60°C, then alkylated with 2 mM iodoacetamide for 45 minutes at room temperature. Trypsin (Promega) was added at a 1:100 enzyme:substrate ratio and digested overnight at 37°C. Following digestion, samples were concentrated using C18 ZipTips (Millipore) according to the manufacturer's specifications. Desalted samples were evaporated to dryness and resuspended in 0.1% formic acid for mass spectrometry analysis.

Peptides were resuspended in 0.1% formic acid and 3% directly injected on a 75 μm ID column (New Objective) packed with 25 cm of Reprosil C18 3 μm , 120 Å particles (Dr. Maisch). Peptides were eluted in positive ion mode into an Orbitrap Elite mass spectrometer (Thermo Fisher) via a Nanospray Flex Ion Source (Thermo Fisher). Elution of peptides was achieved by an acetonitrile gradient delivered at a flow rate of 400 nL/min by an Easy1000 nLC system (Thermo Fisher). All mobile phases contained 0.1% formic acid as buffer A. The total gradient time was 70 minutes, during which mobile phase buffer B (0.1% formic acid in 90% acetonitrile) was ramped from 5% to 30% B over 55 minutes, followed by a ramp to 100% buffer B over a subsequent 5 minutes, and held at 100% for 10 minutes to wash the column. MS data was collected over the first 60 minutes of the gradient. The ion transfer tube was set to 180°C and the spray voltage was 1500V. MS1 scan was collected in the ion trap in centroid mode with 120K resolution over a scan range of 200–2000 m/z, an S-Lens RF of 68%, a 50 ms maximum injection time, and a AGC target of 3e4. Species with a charge state $z = 1$ or unassigned charge states were excluded from selection for MS/MS. Resonance excitation MS/MS was performed on the 20 most abundance precursors with a minimum signal intensity of 200, an isolation width of 2 m/z, a 0.25 activation Q, a 10 ms activation time, a 100 ms maximum injection time, and an AGC target of 1e3. Dynamic exclusion was employed to exclude a list of 50 previously selected precursors within 180 seconds and using a +/- 1.5 Da window.

The results raw data was matched to protein sequences as previously described [62].

Western blot

Cells were lysed using RIPA buffer (Pierce) supplemented with Complete Mini EDTA-free Protease Inhibitor (Roche). Lysate protein concentration was determined using BCA protein assay kit (Pierce). Proteins were separated with denaturing PAGE 4–20% Mini-PROTEAN TGX Pre-cast Protein gel (Bio-Rad) and transferred to Trans-Blot Turbo Mini Nitrocellulose (Bio-Rad) using Trans-Blot Turbo Transfer System (Bio-Rad). Membranes were blocked with LI-COR Odyssey blocking buffer for 1 hour at room temperature with agitation. Primary antibodies were added and incubated overnight at 4°C with agitation. Primary antibodies used were anti-Gal-3 (SCBT sc-32790, primary 1:1000, secondary 1:5000), anti-Gal-8 (Abcam ab69631, primary 1:500, secondary 1:5000), anti-Gal-9 (Abcam ab69630, primary 1:500, secondary 1:5000), anti- β -actin (SCBT sc-47778, primary 1:1000, secondary 1:5000), anti-FLAG (Sigma F3165, primary 1:1000, secondary 1:5000). Secondary antibodies used were LI-COR IRDye 680RD or 800CW goat anti-mouse IgG or anti-rabbit IgG and used at dilutions indicated above. Following primary stain, blots were washed three times 5 minutes each in PBS or PBS 0.1% Tween 20 (PBS-T). Secondary antibodies were incubated for 30 minutes at room temperature with agitation. Blots were washed three times prior to imaging on a LI-COR Odyssey imaging system. PBS-T was used for washing all immunoblots, except anti-Gal-8 and anti-Gal-9 immunoblots, which used PBS no tween for washes. Blots were imaged on a LI-COR Odyssey imaging system.

Bacterial and fungal cultures

***Mycobacterium tuberculosis*.** All *Mtb* experiments were performed with *Mtb* Erdman strain or strains derived from *Mtb* Erdman strain. Low passage frozen stocks of *Mtb* were grown to log phase in 7H9 (BD) liquid media supplemented with 10% Middlebrook OADC (Sigma), 0.05% Tween-80 and 0.5% glycerol in roller bottles at 37°C. *Mtb*-LUX expressing luciferase from the *luxCDABE* operon has been described previously and was cultured as described above [36]. WT or $\Delta eccC$ *Mtb* expressing eGFP under control of the MOP promoter was a gift from Dr. Sarah Stanley's laboratory [63], and was cultured as described above. For BMM infections, log phase bacteria were washed twice with PBS and sonicated three times at 90% amplitude for 30 seconds each then diluted into BMM media (DMEM with 10% FBS, 2 mM L-glutamine, 10% MCSF, 11 mg/mL sodium pyruvate) prior to infection. For THP-1 and RAW 264.7 infections, 10 mL of the *Mtb* culture was washed twice in PBS with 10% heat-inactivated horse serum. After washing, *Mtb* was resuspended in 5 mL PBS with 10% heat-inactivated horse serum and sonicated twice at 50% amplitude for 15 seconds. *Mtb* was diluted into DMEM with 10% heat-inactivated horse serum, and this inoculum was added to THP-1 cells prior to spinfection.

***Salmonella enterica* serovar Typhimurium.** For pathogen pull-down experiments, *Stm* strain SL1344 was cultured overnight at 37°C with shaking in Luria-Bertani (LB) broth and backdiluted 1:100 1 day prior to infection, then allowed to recover to mid-log. BMM infections were performed with *Stm* strain IR715. For mouse infections, *Stm* strain IR715 was cultured in LB broth overnight at 37°C with shaking.

***Listeria monocytogenes*.** All *Lm* strains used in this study were derived from strain 10403S (streptomycin-resistant). $\Delta actA$ PlcA^{H86A} PlcB^{H69G} has been previously described [38]. For macrophage infections, *Lm* was grown to stationary phase overnight, slanted at 30°C in filter-sterilized BHI media with 200 µg/mL streptomycin then diluted into PBS for OD600 measurement and inoculum preparation.

***Legionella pneumophila*.** All *Lp* strains used are JR32 and express the *Photobacterium luminescens luxCDABE* operon. *LuxCDABE*-expressing WT or isogenic mutant for *flaA* have been previously described [64]. Bacteria were cultured in Charcoal-Yeast Extract Agar (CYE, 10 g/L 4-morpholinepropanesulfonic acid [MOPS], 10 g/L Yeast extract, 15 g/L technical agar, 2 g/L activated charcoal, supplemented with 0.4 g/L L-cysteine and 0.135 g/L Fe(NO₃)₃) at 35–37°C for 4 days from frozen stocks. Single colonies were grown on fresh plates for another 2 days. For macrophage infections, bacteria were grown on solid plates and resuspended in autoclaved water and diluted in RPMI.

***Cryptococcus neoformans*.** *Cn* Serotype A strain H99 was grown in yeast culture conditions on YPAD medium [1% yeast extract, 2% Bacto-peptone, 2% glucose, 0.015% L-tryptophan, 0.004% adenine] at 30°C. Cells were harvested mid-log phase for in vitro binding studies.

Cell culture

Primary murine bone marrow-derived macrophages (BMMs) were isolated and cultured in BMM media (DMEM with 10% FBS, 2 mM L-glutamine, 10% MCSF, 11 mg/mL sodium pyruvate) as previously described [22]. For all experiments, BMMs were thawed and allowed to equilibrate for three days prior to replating. THP-1 cells were cultured in RPMI 1640 medium supplemented with 1 mM sodium pyruvate, 10mM HEPES, 4.5 g/L glucose, 0.05 mM 2-mercaptoethanol, 2 mM L-glutamine, 5% fetal calf serum, and 5% bovine growth serum. THP-1 cells were maintained at a concentration between 2e5 cells/mL and 1e6 cells/mL. RAW 264.7 macrophages were cultured in DMEM, 10% FBS, 2 mM L-glutamine, 10 mM HEPES.

To generate Gal-9-3xFLAG cells, RAW 264.7 macrophages were transduced with lentiviral particles containing Gal-9-3xFLAG expressed from pLenti-puro (Addgene #39481). To generate Gal-9^{-/-} and Gal-3^{-/-} cells, RAW 264.7 macrophages were transduced with lentiviral particles containing lentiCRISPR v2 (Addgene #52961) expressing Cas9 and sgRNAs. The following sgRNAs were used: ACGGACAGTGGGGTCCTG (Gal-9), CCCC GGCCCAACT GCCCC (Gal-3). Cells were genotyped and frameshift mutations were confirmed by Sanger sequencing. To generate Gal-9 shRNA knockdown THP-1 cells, shRNAs were designed to target human Gal-9 mRNA and cloned into the pLKO.1 vector (Addgene #10878). The sense shRNA sequences are CCTGGTGCAGAGCTCAGATTT (shGal-9 #1) and GCTCTGTGC AGCTGTCCTA (shGal-9 #2). Lentiviral particles were produced in Lenti-X cells (Clontech) per manufacturer's instructions. Early passage THP-1 cells were transduced with lentiviral particles containing the shRNA expression vector. The cells were selected in 0.5 μg/mL puromycin to obtain a polyclonal population. Knockdown efficiency was assessed via qPCR using the following primers: 5'-CCGAAAATGCCCTTCGTCC-3' (forward), 5'-ACCTTGAGGCAGT GAGCTTC-3' (reverse) and determined to be 95% and 91% knockdown for shGal-9 #1 and shGal-9 #2, respectively.

LLOMe and bafilomycin A1 treatment

For lysosomal damage experiments, BMMs were incubated with LLOMe (Sigma) at the indicated concentrations for 2 hours prior to fixation. For the autophagic flux experiments, *Mtb*-infected BMMs were treated with vehicle control (DMSO) or bafilomycin A1 (Sigma) at the indicated concentrations for 3 hours prior to fixation.

Macrophage infections

***Mycobacterium tuberculosis*.** To ensure bacterial replication or autophagy targeting was not impacted by differences in macrophage concentration, WT BMMs were plated in 96-well plates at the target cell density, while TKO BMMs were plated on a cell density gradient in order to ensure equivalent plating numbers of each genotype. After plating, cells were allowed to adhere and equilibrate for 2 to 3 days prior to infection. On day 0 of infection, one plate was fixed in PBS with 4% PFA, washed, DAPI stained, and nuclei were counted at 5X magnification on an Opera Phenix microscope, thus allowing determination of cell density-matched wells. During analysis, wells of different genotypes were only compared if cell counts were matched within <5% of each other. For microscopy, CFU, and *Mtb*-LUX experiments, cells were infected by removing media from wells, overlaying cell monolayers with bacterial suspensions, and spinfecting for 10 minutes at 300 rcf.

For *Mtb*-LUX infections, cells were plated at 4×10^4 cells per well (target density) in Nunc 96-well white walled TC treated plates (Thermo Fisher). For IFN-γ treatment, cells were incubated with 1.5 ng/mL IFN-γ the day before infection. BMMs were infected at a MOI of 1 or 5. Luminescence of *Mtb*-LUX-infected BMMs in cell density-matched wells was measured as previously described [62].

For all *Mtb* microscopy experiments, WT *Mtb*-GFP or Δ eccC *Mtb*-GFP were used. BMMs were plated in either 24-well glass-bottom plates (Cellvis) at 2×10^5 cells per well, or 96-well PerkinElmer Cell Carrier Ultra plates at 2.5×10^4 cells per well (target density). All infections for microscopy used an MOI of 2. At indicated time points, microscopy plates were washed in warm PBS, fixed in PBS with 4% PFA, washed three times with PBS, and stored in PBS at 4°C before immunostaining. For lysotracker experiments, cells were stained with 50 nM Lyso-tracker Red DND-99 in BMM media for 3 hours prior to fixation and imaged immediately after washing out the fixative.

For *Mtb* CFU experiments, BMMs were plated in 24-well TC treated plates at 2×10^5 cells per well, infected with WT *Mtb* Erdman strain using an MOI of 2, and *Mtb* CFU enumeration was performed as previously described [63].

For *Mtb* infection of THP-1 cells, THP-1 cells were differentiated for 3 days in DMEM with 2 mM L-glutamine, 1 mM sodium pyruvate, and 10% heat-inactivated fetal calf serum with 10 ng/mL PMA and 0.1 ng/mL Vitamin D. On day 0 of differentiation, THP-1 cells were plated at 4×10^4 cells per well in a 96-well plate. The media was exchanged with fresh differentiation media daily. Bacterial suspension was prepared as described above and THP-1 cells were spininfected for 5 minutes. Cells were incubated at 37°C for 30 minutes. THP-1 cells were washed 3 times with PBS with 1% heat-inactivated horse serum. Differentiation media lacking phenol red with PMA and Vitamin D was replaced after the washes. Luminescence of *Mtb*-LUX-infected THP-1 cells was measured as previously described [62]. Half of the media was discarded and replaced with fresh differentiation media with PMA and Vitamin D on days 1, 3, and 5 post-infection.

***Salmonella enterica* serovar Typhimurium.** 1×10^5 BMMs were plated on 24-well plates 24 hours prior to infection. For IFN- γ treatment, cells were incubated with 0.01 $\mu\text{g}/\text{mL}$ IFN- γ the night before infection. Bacteria grown to mid-log phase as described above were pelleted and resuspended in BMM media. Suspension was incubated at 37°C for 30 minutes for opsonization. Bacteria were then pelleted and resuspended to 1×10^9 CFU/mL prior to spininfection with BMMs for 5 minutes at 250 rcf followed by 37°C incubation for 30 minutes for phagocytosis. Cells were washed with PBS and incubated with BMM media with 100 $\mu\text{g}/\text{mL}$ gentamicin at 37°C incubation for 30 minutes, then washed with PBS and incubated with BMM media with 5 $\mu\text{g}/\text{mL}$ gentamicin. For CFU enumeration, cells were washed with PBS and lysed in 500 μL water for 10 minutes prior to lysate serial dilution and plating on LB agar plates.

Listeria monocytogenes. A total of 3×10^6 BMMs were plated on 14 coverslips in 60 mm non-TC treated dishes and infected the next day at an MOI of 0.25. *Lm* CFU enumeration was performed as previously described [65].

Legionella pneumophila. Bacterial replication was measured using a luminescence-based replication assay as previously described [66]. Briefly, 10^5 WT or TKO BMMs were plated on 96-well plates and incubated overnight. Medium was replaced with bacterial suspension in BMM media at an MOI of 0.01. At indicated time points, luminescence emission was measured at 470 nm with a Spectra-L plate reader (Molecular Devices).

Immunofluorescence

Following fixation, washing, and storage in PBS at 4°C, cells were blocked and permeabilized in PBS with 5% FBS or 2% BSA and 0.1% Triton X-100 (blocking/permeabilization buffer) for 30 minutes at room temperature. For LC3 immunostaining, cells were incubated with ice cold methanol for 10 minutes on ice, then washed three times with PBS prior to the blocking and permeabilization step above. Cells were then stained in blocking/permeabilization buffer overnight at 4°C with the following primary antibodies at the indicated dilutions: anti-Gal-9 (Abcam ab275877, primary 1:100, secondary 1:500), anti-Gal-3 (SCBT sc-32790, primary 1:50, secondary 1:500), anti-polyubiquitin (Millipore Sigma ST1200, primary 1:400, secondary 1:2000), anti-ubiquitin K63-specific (Millipore Sigma 05-1308, primary 1:200, secondary 1:2000), anti-ubiquitin K48-specific (Millipore Sigma 05-1307, primary 1:200, secondary 1:2000), anti-p62 (Abcam ab109012, primary 1:400, secondary 1:4000), anti-Tax1bp1 (Bethyl Laboratories A303-791A, primary 1:200, secondary 1:1000), anti-Optineurin (Bethyl Laboratories A301-829A, primary 1:200, secondary 1:1000), and anti-LC3 (Nanotools 0260-100/LC3-2G6, primary 1:400, secondary 1:2000). Cells were then washed three times with PBS for 5 minutes each. DAPI and secondary antibody staining was performed at room temperature for

30–60 minutes using anti-mouse or anti-rabbit Alexa Fluor 647 or 488 (Invitrogen) at the above indicated dilutions. Cells were washed three times with PBS for 5 minutes then imaged.

Automated confocal microscopy and image analysis

All microscopy experiments were performed with an Opera Phenix High-Content Screening System confocal microscope (PerkinElmer). Microscopy plates were imaged at 10X magnification for nuclei counting and cell density matching, 40X or 63X magnification for colocalization or puncta quantification, or 63X magnification for representative images. Automated analysis for colocalization, nuclei counting, and puncta quantification was performed with PerkinElmer Harmony software package. For colocalization analysis, a maximum intensity projection was generated from multiple z-stacks and autophagy markers and bacteria were identified using a spot finder algorithm. Autophagy marker spots were then filtered based on size and only spots >25–40 pixels in area were selected for analysis to limit nonspecific colocalization of small puncta with bacteria. Bacteria with at least one pixel of overlap with size filtered autophagy marker spots were counted as a colocalization event, and % colocalization was defined as the total number of colocalization events divided by the total number of bacteria.

Electron-microscopy

RAW 264.7 cells expressing mouse Gal-9-3xFLAG were infected with *Mtb* at an MOI of 1 for 6 hours. Cells were then detached using 1 mM EDTA in PBS and fixed for 10 minutes at room temperature using freshly prepared periodate-lysine-paraformaldehyde stain (0.2 M lysine-HCl pH 7.4, 4% paraformaldehyde, 0.1 M sodium m-periodate). Following fixation, cells were pelleted and resuspended in PBS without washing and stored at 4° until embedding was performed. Samples were embedded in 10% gelatin and infiltrated overnight with 2.3 M sucrose/20% polyvinyl pyrrolidone in PIPES/MgCl₂ at 4°C. Samples were trimmed, frozen in liquid nitrogen, and sectioned with a Leica Ultracut UCT7 cryo-ultramicrotome (Leica Microsystems). Ultrathin sections of 50 nm were blocked with 5% FBS/5% NGS for 30 minutes and subsequently incubated with mouse anti-FLAG (Sigma F3165) for 1 hour at room temperature. Following washes in block buffer, sections were incubated with goat anti-mouse IgG + IgM 18 nm colloidal gold conjugated secondary antibody (Jackson ImmunoResearch Laboratories) for 1 hour. Sections were stained with 0.3% uranyl acetate/2% methyl cellulose and viewed on a JEOL 1200 EX transmission electron microscope (JEOL USA) equipped with an AMT 8 megapixel digital camera and AMT Image Capture Engine V602 software (Advanced Microscopy Techniques). All labeling experiments were conducted in parallel with controls omitting the primary antibody.

Mice

All mice used were specific pathogen free, maintained in 12 hour light-dark cycle, and given standard chow diet ad libitum. 8 to 12-week-old male and female mice were used. WT C57BL/6J mice were obtained from Jackson Laboratories (JAX). CRISPR/Cas9 targeting was performed by electroporation of Gal-3, Gal-8, and Gal-9-targeting Cas9-sgRNA RNP complexes into fertilized zygotes from C57BL/6J female mice (JAX, stock no. 000664) [67]. TKO mice were generated by targeting exon 1 of each galectin using two guides per exon; sgRNA sequences: 5'-GGCTGGTTCCTCCATGCACC-3' and 5'-CTCCAGGGGCAGTTGGGCCG-3' (Gal-3), 5'-CAGCTAGACCTTTTGAACCG-3' and 5'-CACCATGAACACGATCTCAA-3' (Gal-8), and 5'-TACCCTCCTTCTCAAACCG-3' and 5'-GAACGGACAGTGGGGTCCTG-3' (Gal-9). Founder mice were genotyped by PCR amplifying the targeted exons from mouse tail DNA, followed by Sanger sequencing to identify mice carrying mutations. The following

primers were used: Gal-3 PCR fwd tgtgaatcttctccatgtccagc; Gal-3 PCR rev tcctcttaccagtggtc-cagc; Gal-3 seq agatcacaaatgcctgtagtc; Gal-8 PCR fwd tccatataagccagctcatgctgtgg; Gal-8 PCR rev gcctcctagaagaagtaagacctaagg; Gal-8 seq ctaagtttatctgttccatctgg; Gal-9 PCR fwd atga-cattgcctccactcaacc; Gal-9 PCR rev tcaaaggcatccccttctgg; Gal-9 seq cacctcaggcagtcag. Mice with mutations were bred to WT C57BL/6J mice to separate modified haplotypes. Homozygous lines were generated by interbreeding heterozygotes carrying matched haplotypes. Two independent TKO mouse lines were established. TKO strain 1 (Gal-3, 34nt deletion; Gal-8, 1nt insertion; Gal-9, 58 nt deletion) was used for the *Mtb*, *Lm*, and *Lp* experiments. TKO strain 2 (Gal-3, 5nt deletion; Gal-8, 103nt deletion; Gal-9, 17nt deletion) was used for the *Stm* macrophage and mouse experiments.

***Mycobacterium tuberculosis* aerosol infection**

To prepare infection inoculum, *Mtb* Erdman strain frozen stock was diluted in sterile water and sonicated at 90% amplitude three times for 30 seconds. 8 to 12-week-old male and female mice were infected with approximately ~75 CFUs (conventional dose) or >400 CFUs (high dose) of prepared inoculum using a Glas-Col inhalation exposure system. At indicated time points, lungs and spleens were isolated, homogenized, and plated on 7H10 plates with Polymyxin B (200,000 U/L), Carbenicillin (50 mg/L), Trimethoprim lactate (20 mg/L) and Amphotericin B (5 mg/L). Plates were incubated at 37°C for 25–28 days before counting colonies. For survival experiment, mouse weight was measured weekly and mice were sacrificed after losing 15% of maximum body weight.

***Salmonella enterica* serovar Typhimurium intraperitoneal infection**

Stm strain IR715 was cultured as described above. Mice received 100 µl of sterile PBS or 1000 CFUs diluted in 100 µl PBS by intraperitoneal injection. Mouse weights were monitored daily during infection. Systemic bacterial levels were characterized at day 1, 2, or 3 post-infection by harvesting liver and spleen and enumerating CFU. Liver and spleen were collected in PBS, weighed, and homogenized. Homogenates were serially diluted and plated on LB agar plates. CFU per gram tissue was calculated after overnight growth at 37°C.

***Listeria monocytogenes* intravenous infection**

Lm was grown at 37°C with shaking at 200 rpm to mid-log phase. Bacteria were washed in PBS and resuspended at 5×10^5 colony-forming units (CFU) per 1 mL of sterile PBS. Mice were then injected with 1×10^5 CFU via the tail vein. 48 hours post-infection, livers and spleens were collected, homogenized, and plated on LB streptomycin 200 µg/mL to determine the number of CFU per organ.

Interferon- γ enzyme-linked immunospot (ELISpot)

Spleens were isolated and pressed through a 70 µm cell strainer to generate a single cell suspension. Lung cells were isolated and digested in RPMI with Liberase TM (70 µg/ml) and DNase I (30 µg/ml) in gentleMACS C-tubes then placed at 37°C for 30 minutes, followed by gentleMACS tissue homogenization for single cell suspension. Cells were pelleted and RBCs were lysed using ACK lysing buffer. Cells were washed, pelleted, resuspended in X-VIVO TM 15 (Lonza) and counted on a hemocytometer or using fluorescent count beads on an SH800 Sony Sorter. Cells were plated, stimulated overnight with indicated peptides (2 µg/ml) or Concanavalin A (ConA, 2.5 µg/ml), developed, and analyzed as previously described [68]. ConA-stimulated cells were used as a positive control and to determine total cell counts. IFN- γ spot-

forming cell (SFC) counts from peptide-stimulated wells were normalized to SFC counts from ConA-stimulated wells to control for differences in cell density between samples.

Statistical analysis

Analysis of statistical significance was performed with Prism 9 (GraphPad).

Supporting information

S1 Fig. Gal-9 localization during *Mtb* infection. (A) Cryosections of RAW 264.7 cells stably expressing Gal-9-FLAG infected with WT *Mtb* (MOI = 1) 6 hours post-infection. Gal-9 localization to extra-phagosomal membranes (black arrowheads), phagosomes (black arrows), and *Mtb* (white arrowheads); b, bacteria. Four representative micrographs are shown from a dataset of 26 total images. Scale bar = 0.5 μ m. (B) Quantification of (A) for Gal-9-FLAG localization to indicated structures; EP membrane, extra-phagosomal membranes. Values are a percent of total Gal-9-FLAG puncta in the dataset.

(TIFF)

S2 Fig. Generation and validation of Gal-3, -8, and -9 triple knockout (TKO) mice. (A) Immunoblots of bone marrow-derived macrophage (BMM) lysates from WT and TKO mice (strain 2) probed for indicated proteins. (B) Confocal microscopy of WT or TKO BMMs treated with LLOMe at the indicated concentrations for 2 hours and immunostained for LC3. (C) Quantification of (B) for LC3 puncta per cell. Figures are representative of three independent experiments (B, C). An average of 400 cells were analyzed per technical replicate (C).

Error bars represent SD from four technical replicates, and ** $p < 0.01$, *** $p < 0.001$ by unpaired t-test.

(TIFF)

S3 Fig. Recruitment of autophagy markers to *Mtb*. (A) Confocal microscopy of WT or TKO BMMs infected with *Mtb*-GFP (MOI = 2) 8 hours post-infection and immunostained for K48- or K63-linked polyubiquitin, or p62. (B) Quantification of (A) for *Mtb*-GFP colocalization with indicated markers. (C) Confocal microscopy of WT or TKO BMMs infected with *Mtb*-GFP (MOI = 2) 8 hours post-infection and immunostained for p62, Tax1bp1, or Optineurin. (D) Quantification of (C) for *Mtb*-GFP colocalization with indicated markers. (E) Quantification of polyubiquitin puncta 8 hours post-infection in mock- or *Mtb*-GFP-infected (MOI = 2) WT or TKO BMMs. (F) Quantification of Lysotracker puncta 8 hours post-infection in mock- or *Mtb*-GFP-infected (MOI = 2) WT or TKO BMMs. (G) Quantification of LC3 colocalization with WT or Δ *eccC* *Mtb* (MOI = 2) at indicated time points. Figures are representative of two (A-D) independent experiments or represent one (G) or two (E, F) independent experiments. An average of 747 (A, B), 926 (C, D), 1464 (E, F), and 429 (G) cells were analyzed per technical replicate. Error bars represent SD from three (E, F) or four (A-D, G) technical replicates, and ** $p < 0.01$, *** $p < 0.0001$ by unpaired t-test.

(TIFF)

S4 Fig. Galectin single knockdown or knockout macrophage infections. RLU-fold change of (A) control or Gal-9 knockdown shRNA THP-1 cells infected with *Mtb*-LUX (MOI = 1), (B) control, Gal-3^{-/-}, or Gal-9^{-/-} RAW 264.7 cells infected with *Mtb*-LUX (MOI = 1), (C) WT or Gal-9^{-/-} BMMs infected with *Mtb*-LUX (MOI = 2), or (D) Gal-8^{+/-} or Gal-8^{-/-} BMMs infected with *Mtb*-LUX (MOI = 1). Figures are representative of two (B, D) or three (C) independent experiments, or represent four independent experiments (A). Error bars represent SD from three technical replicates, and ** $p < 0.01$, *** $p < 0.001$ by unpaired t-test.

(TIFF)

S5 Fig. Lung CFU data for *Mtb* aerosol infections. WT and TKO female mice were aerosol infected with (A) ~18 CFUs or (B) ~136 CFUs of *Mtb* Erdman and bacterial loads in lungs were enumerated by plating for CFU at indicated time points. $n = 3-5$ mice per genotype. Figures represent one experiment. Bars represent the mean, error bars represent SEM, and p-values were determined by unpaired t-test.

(TIFF)

S6 Fig. Membrane damage sensing galectins are partially required for control of *Mtb* in a high-dose aerosol infection. (A) WT and TKO male mice were aerosol infected with ~450 CFUs of *Mtb* Erdman and bacterial loads in lungs were enumerated by plating for CFU at indicated time points. $n = 5$ mice per genotype. (B) Same as in (A) but bacterial loads in spleens. Figures represent one experiment. Bars represent the mean, error bars represent SEM, and p-values were determined by unpaired t-test.

(TIFF)

S7 Fig. TKO mice exhibit defective splenic Ag85B-specific T cell responses. (A) WT and TKO mice were aerosol infected with ~100 CFUs of *Mtb* Erdman and splenocytes were isolated for IFN- γ ELISpot to enumerate *Mtb*-specific T cells. *Mtb*-specific spot-forming cells (SFC) responding to re-stimulation in vitro with *Mtb* peptides are shown for each condition relative to Concanavalin A (ConA) total T cells and WT. $n = 10-11$ mice per genotype. (B) Same as in (A) but ELISpot performed with lung single cell suspension. $n = 4$ mice per genotype. (C) ELISpot on splenocytes following high-dose aerosol inoculation (~800 CFUs). $n = 5$ mice per genotype. Figures represent data from three (A) independent experiments or one (B, C) independent experiment. Error bars represent SD, and **** $p < 0.0001$ by unpaired t-test.

(TIFF)

S1 Table. *Mtb* pull-down mass spectrometry results.

(XLSX)

Acknowledgments

We thank Erika Oki, Justin Paluba, Rita McCall, Miles Tuncel, Laura Flores, Christopher Noel, Dmitri Kotov, Danielle Swaney, Hannah Nilsson, Michael Cronce, Allison Roberts, and Chris Rae for technical assistance. We thank Dr. Mary West and Dr. Deepa Sridharan of the High-Throughput Screening Facility (HTSF) at UC Berkeley. This work was performed in part in the HTSF, which provided the Opera Phenix microscope, funded by NIH S10OD021828. Finally, we thank James Olzmann and members of the Cox, Vance, and Stanley labs for helpful discussions.

Author Contributions

Conceptualization: Huntly M. Morrison, Bennett H. Penn, Jeffery S. Cox.

Data curation: Jeffery R. Johnson.

Formal analysis: Huntly M. Morrison, Julia Craft, Jeffery R. Johnson, Samantha L. Bell, Bennett H. Penn.

Funding acquisition: Russell E. Vance, Sarah A. Stanley, Daniel A. Portnoy, Bennett H. Penn, Jeffery S. Cox.

Investigation: Huntly M. Morrison, Julia Craft, Rafael Rivera-Lugo, Jeffery R. Johnson, Guillaume R. Golovkine, Samantha L. Bell, Claire E. Dodd, Erik Van Dis, Wandy L. Beatty, Shally R. Margolis, Teresa Repasy, Isaac Shaker, Angus Y. Lee, Bennett H. Penn.

Methodology: Huntly M. Morrison, Julia Craft, Rafael Rivera-Lugo, Wandy L. Beatty, Shally R. Margolis, Bennett H. Penn.

Software: Jeffery R. Johnson.

Supervision: Russell E. Vance, Sarah A. Stanley, Robert O. Watson, Nevan J. Krogan, Daniel A. Portnoy, Bennett H. Penn, Jeffery S. Cox.

Writing – original draft: Huntly M. Morrison.

Writing – review & editing: Huntly M. Morrison, Julia Craft, Rafael Rivera-Lugo, Jeffery R. Johnson, Guillaume R. Golovkine, Samantha L. Bell, Claire E. Dodd, Erik Van Dis, Wandy L. Beatty, Shally R. Margolis, Teresa Repasy, Isaac Shaker, Angus Y. Lee, Russell E. Vance, Sarah A. Stanley, Robert O. Watson, Nevan J. Krogan, Daniel A. Portnoy, Bennett H. Penn, Jeffery S. Cox.

References

1. Thakur A, Mikkelsen H, Jungersen G. Intracellular Pathogens: Host Immunity and Microbial Persistence Strategies. *J Immunol Res*. 2019; 2019: 1356540. <https://doi.org/10.1155/2019/1356540> PMID: 31111075
2. Price J V, Vance RE. The macrophage paradox. *Immunity*. 2014; 41: 685–693. <https://doi.org/10.1016/j.immuni.2014.10.015> PMID: 25517611
3. Watson RO, Bell SL, MacDuff DA, Kimmey JM, Diner EJ, Olivas J, et al. The Cytosolic Sensor cGAS Detects Mycobacterium tuberculosis DNA to Induce Type I Interferons and Activate Autophagy. *Cell Host Microbe*. 2015; 17: 811–819. <https://doi.org/10.1016/j.chom.2015.05.004> PMID: 26048136
4. Kofoed EM, Vance RE. Innate immune recognition of bacterial ligands by NAIPs determines inflammatory specificity. *Nature*. 2011; 477: 592–595. <https://doi.org/10.1038/nature10394> PMID: 21874021
5. Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system. *Nat Immunol*. 2015; 16: 343–353. <https://doi.org/10.1038/ni.3123> PMID: 25789684
6. Ravesloot-Chávez MM, Van Dis E, Stanley SA. The Innate Immune Response to Mycobacterium tuberculosis Infection. *Annu Rev Immunol*. 2021; 39: 611–637. <https://doi.org/10.1146/annurev-immunol-093019-010426> PMID: 33637017
7. Paz I, Sachse M, Dupont N, Mounier J, Cederfur C, Enninga J, et al. Galectin-3, a marker for vacuole lysis by invasive pathogens. *Cell Microbiol*. 2010; 12: 530–544. <https://doi.org/10.1111/j.1462-5822.2009.01415.x> PMID: 19951367
8. Dupont N, Lacas-Gervais S, Bertout J, Paz I, Freche B, Van Nhieu GT, et al. Shigella phagocytic vacuolar membrane remnants participate in the cellular response to pathogen invasion and are regulated by autophagy. *Cell Host Microbe*. 2009; 6: 137–149. <https://doi.org/10.1016/j.chom.2009.07.005> PMID: 19683680
9. Thurston TLM, Wandel MP, von Muhlinen N, Foeglein A, Randow F. Galectin 8 targets damaged vesicles for autophagy to defend cells against bacterial invasion. *Nature*. 2012; 482: 414–418. <https://doi.org/10.1038/nature10744> PMID: 22246324
10. Rabinovich GA, Liu F-T, Hirashima M, Anderson A. An emerging role for galectins in tuning the immune response: lessons from experimental models of inflammatory disease, autoimmunity and cancer. *Scand J Immunol*. 2007; 66: 143–158. <https://doi.org/10.1111/j.1365-3083.2007.01986.x> PMID: 17635792
11. Rabinovich GA, Toscano MA. Turning “sweet” on immunity: galectin-glycan interactions in immune tolerance and inflammation. *Nat Rev Immunol*. 2009; 9: 338–352. <https://doi.org/10.1038/nri2536> PMID: 19365409
12. Cummings RD, Liu F-T. Galectins. In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, et al., editors. *Cold Spring Harbor (NY)*; 2009.
13. Jayaraman P, Sada-Ovalle I, Beladi S, Anderson AC, Dardalhon V, Hotta C, et al. Tim3 binding to galectin-9 stimulates antimicrobial immunity. *J Exp Med*. 2010; 207: 2343–2354. <https://doi.org/10.1084/jem.20100687> PMID: 20937702

14. Maejima I, Takahashi A, Omori H, Kimura T, Takabatake Y, Saitoh T, et al. Autophagy sequesters damaged lysosomes to control lysosomal biogenesis and kidney injury. *EMBO J*. 2013; 32: 2336–2347. <https://doi.org/10.1038/emboj.2013.171> PMID: 23921551
15. Chauhan S, Kumar S, Jain A, Ponpuak M, Mudd MH, Kimura T, et al. TRIMs and Galectins Globally Cooperate and TRIM16 and Galectin-3 Co-direct Autophagy in Endomembrane Damage Homeostasis. *Dev Cell*. 2016; 39: 13–27. <https://doi.org/10.1016/j.devcel.2016.08.003> PMID: 27693506
16. Jia J, Abudu YP, Claude-Taupin A, Gu Y, Kumar S, Choi SW, et al. Galectins Control mTOR in Response to Endomembrane Damage. *Mol Cell*. 2018; 70: 120–135.e8. <https://doi.org/10.1016/j.molcel.2018.03.009> PMID: 29625033
17. Jia J, Claude-Taupin A, Gu Y, Choi SW, Peters R, Bissa B, et al. Galectin-3 Coordinates a Cellular System for Lysosomal Repair and Removal. *Dev Cell*. 2020; 52: 69–87.e8. <https://doi.org/10.1016/j.devcel.2019.10.025> PMID: 31813797
18. Jia J, Bissa B, Brecht L, Allers L, Choi SW, Gu Y, et al. AMPK, a Regulator of Metabolism and Autophagy, Is Activated by Lysosomal Damage via a Novel Galectin-Directed Ubiquitin Signal Transduction System. *Mol Cell*. 2020; 77: 951–969.e9. <https://doi.org/10.1016/j.molcel.2019.12.028> PMID: 31995728
19. Wong K-W, Jacobs WRJ. Critical role for NLRP3 in necrotic death triggered by *Mycobacterium tuberculosis*. *Cell Microbiol*. 2011; 13: 1371–1384. <https://doi.org/10.1111/j.1462-5822.2011.01625.x> PMID: 21740493
20. Bell SL, Lopez KL, Cox JS, Patrick KL, Watson RO. Galectin-8 Senses Phagosomal Damage and Recruits Selective Autophagy Adapter TAX1BP1 To Control *Mycobacterium tuberculosis* Infection in Macrophages. *MBio*. 2021; 12: e0187120. <https://doi.org/10.1128/mBio.01871-20> PMID: 34225486
21. Feeley EM, Pilla-Moffett DM, Zwack EE, Piro AS, Finethy R, Kolb JP, et al. Galectin-3 directs antimicrobial guanylate binding proteins to vacuoles furnished with bacterial secretion systems. *Proc Natl Acad Sci U S A*. 2017; 114: E1698–E1706. <https://doi.org/10.1073/pnas.1615771114> PMID: 28193861
22. Budzik JM, Swaney DL, Jimenez-Morales D, Johnson JR, Garelis NE, Repasy T, et al. Dynamic post-translational modification profiling of *Mycobacterium tuberculosis*-infected primary macrophages. *Elife*. 2020; 9. <https://doi.org/10.7554/eLife.51461> PMID: 31951200
23. Johnson JR, Parry T, Repasy T, Geiger KM, Verschueren E, Budzik JM, et al. Comparative analysis of macrophage post-translational modifications during intracellular bacterial pathogen infection. *bioRxiv*. 2020; 2020.05.27.116772. <https://doi.org/10.1101/2020.05.27.116772>
24. Pelletier I, Hashidate T, Urashima T, Nishi N, Nakamura T, Futai M, et al. Specific recognition of *Leishmania major* poly-beta-galactosyl epitopes by galectin-9: possible implication of galectin-9 in interaction between *L. major* and host cells. *J Biol Chem*. 2003; 278: 22223–22230. <https://doi.org/10.1074/jbc.M302693200> PMID: 12684513
25. Stowell SR, Arthur CM, Dias-Baruffi M, Rodrigues LC, Gourdin J-P, Heimburg-Molinario J, et al. Innate immune lectins kill bacteria expressing blood group antigen. *Nat Med*. 2010; 16: 295–301. <https://doi.org/10.1038/nm.2103> PMID: 20154696
26. Quattroni P, Li Y, Lucchesi D, Lucas S, Hood DW, Herrmann M, et al. Galectin-3 binds *Neisseria meningitidis* and increases interaction with phagocytic cells. *Cell Microbiol*. 2012; 14: 1657–1675. <https://doi.org/10.1111/j.1462-5822.2012.01838.x> PMID: 22827322
27. Wu X, Wu Y, Zheng R, Tang F, Qin L, Lai D, et al. Sensing of mycobacterial arabinogalactan by galectin-9 exacerbates mycobacterial infection. *EMBO Rep*. 2021; 22: e51678. <https://doi.org/10.15252/embr.202051678> PMID: 33987949
28. Mizushima N. Autophagy: process and function. *Genes Dev*. 2007; 21: 2861–2873. <https://doi.org/10.1101/gad.1599207> PMID: 18006683
29. Levine B, Mizushima N, Virgin HW. Autophagy in immunity and inflammation. *Nature*. 2011; 469: 323–335. <https://doi.org/10.1038/nature09782> PMID: 21248839
30. Golovkine GR, Roberts AW, Morrison HM, Rivera-Lugo R, McCall RM, Nilsson H, et al. Autophagy restricts *Mycobacterium tuberculosis* during acute infection in mice. *Nat Microbiol*. 2023. <https://doi.org/10.1038/s41564-023-01354-6> PMID: 37037941
31. Watson RO, Manzanillo PS, Cox JS. Extracellular *M. tuberculosis* DNA targets bacteria for autophagy by activating the host DNA-sensing pathway. *Cell*. 2012; 150: 803–815. <https://doi.org/10.1016/j.cell.2012.06.040> PMID: 22901810
32. Manzanillo PS, Ayres JS, Watson RO, Collins AC, Souza G, Rae CS, et al. The ubiquitin ligase parkin mediates resistance to intracellular pathogens. *Nature*. 2013; 501: 512–516. <https://doi.org/10.1038/nature12566> PMID: 24005326
33. Franco LH, Nair VR, Scharn CR, Xavier RJ, Torrealba JR, Shiloh MU, et al. The Ubiquitin Ligase Smurf1 Functions in Selective Autophagy of *Mycobacterium tuberculosis* and Anti-tuberculous Host

- Defense. *Cell Host Microbe*. 2017; 21: 59–72. <https://doi.org/10.1016/j.chom.2016.11.002> PMID: 28017659
34. Stolz A, Ernst A, Dikic I. Cargo recognition and trafficking in selective autophagy. *Nat Cell Biol*. 2014; 16: 495–501. <https://doi.org/10.1038/ncb2979> PMID: 24875736
 35. Mellacheruvu D, Wright Z, Couzens AL, Lambert J-P, St-Denis NA, Li T, et al. The CRAPome: a contaminant repository for affinity purification–mass spectrometry data. *Nat Methods*. 2013; 10: 730–736. <https://doi.org/10.1038/nmeth.2557> PMID: 23921808
 36. Braverman J, Sogi KM, Benjamin D, Nomura DK, Stanley SA. HIF-1 α Is an Essential Mediator of IFN- γ -Dependent Immunity to Mycobacterium tuberculosis. *J Immunol*. 2016; 197: 1287–1297. <https://doi.org/10.4049/jimmunol.1600266> PMID: 27430718
 37. Ren T, Zamboni DS, Roy CR, Dietrich WF, Vance RE. Flagellin-deficient Legionella mutants evade caspase-1- and Naip5-mediated macrophage immunity. *PLoS Pathog*. 2006; 2: e18. <https://doi.org/10.1371/journal.ppat.0020018> PMID: 16552444
 38. Mitchell G, Cheng MI, Chen C, Nguyen BN, Whiteley AT, Kianian S, et al. Listeria monocytogenes triggers noncanonical autophagy upon phagocytosis, but avoids subsequent growth-restricting xenophagy. *Proc Natl Acad Sci U S A*. 2018; 115: E210–E217. <https://doi.org/10.1073/pnas.1716055115> PMID: 29279409
 39. Cooper AM. Cell-mediated immune responses in tuberculosis. *Annu Rev Immunol*. 2009; 27: 393–422. <https://doi.org/10.1146/annurev.immunol.021908.132703> PMID: 19302046
 40. Sakai S, Kauffman KD, Schenkel JM, McBerry CC, Mayer-Barber KD, Masopust D, et al. Cutting edge: control of Mycobacterium tuberculosis infection by a subset of lung parenchyma-homing CD4 T cells. *J Immunol*. 2014; 192: 2965–2969. <https://doi.org/10.4049/jimmunol.1400019> PMID: 24591367
 41. Tattoli I, Sorbara MT, Yang C, Tooze SA, Philpott DJ, Girardin SE. Listeria phospholipases subvert host autophagic defenses by stalling pre-autophagosomal structures. *EMBO J*. 2013; 32: 3066–3078. <https://doi.org/10.1038/emboj.2013.234> PMID: 24162724
 42. Mitchell G, Ge L, Huang Q, Chen C, Kianian S, Roberts MF, et al. Avoidance of autophagy mediated by PlcA or ActA is required for Listeria monocytogenes growth in macrophages. *Infect Immun*. 2015; 83: 2175–2184. <https://doi.org/10.1128/IAI.00110-15> PMID: 25776746
 43. Choy A, Dancourt J, Mugo B, O'Connor TJ, Isberg RR, Melia TJ, et al. The Legionella effector RavZ inhibits host autophagy through irreversible Atg8 deconjugation. *Science*. 2012; 338: 1072–1076. <https://doi.org/10.1126/science.1227026> PMID: 23112293
 44. Conway KL, Kuballa P, Song J-H, Patel KK, Castoreno AB, Yilmaz OH, et al. Atg161i is required for autophagy in intestinal epithelial cells and protection of mice from Salmonella infection. *Gastroenterology*. 2013; 145: 1347–1357. <https://doi.org/10.1053/j.gastro.2013.08.035> PMID: 23973919
 45. Kobayashi KS, Chamailard M, Ogura Y, Henegariu O, Inohara N, Nuñez G, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. *Science*. 2005; 307: 731–734. <https://doi.org/10.1126/science.1104911> PMID: 15692051
 46. Castillo EF, Dekonenko A, Arko-Mensah J, Mandell MA, Dupont N, Jiang S, et al. Autophagy protects against active tuberculosis by suppressing bacterial burden and inflammation. *Proc Natl Acad Sci U S A*. 2012; 109: E3168–76. <https://doi.org/10.1073/pnas.1210500109> PMID: 23093667
 47. Kimmey JM, Huynh JP, Weiss LA, Park S, Kambal A, Debnath J, et al. Unique role for ATG5 in neutrophil-mediated immunopathology during M. tuberculosis infection. *Nature*. 2015; 528: 565–569. <https://doi.org/10.1038/nature16451> PMID: 26649827
 48. Guo M, Härtlova A, Dill BD, Prescott AR, Gierliński M, Trost M. High-resolution quantitative proteome analysis reveals substantial differences between phagosomes of RAW 264.7 and bone marrow derived macrophages. *Proteomics*. 2015; 15: 3169–3174. <https://doi.org/10.1002/pmic.201400431> PMID: 25504905
 49. Bagaev A V, Garaeva AY, Lebedeva ES, Pichugin A V, Ataulakhanov RI, Ataulakhanov FI. Elevated pre-activation basal level of nuclear NF- κ B in native macrophages accelerates LPS-induced translocation of cytosolic NF- κ B into the cell nucleus. *Sci Rep*. 2019; 9: 4563. <https://doi.org/10.1038/s41598-018-36052-5> PMID: 30872589
 50. Tumbarello DA, Manna PT, Allen M, Bycroft M, Arden SD, Kendrick-Jones J, et al. The Autophagy Receptor TAX1BP1 and the Molecular Motor Myosin VI Are Required for Clearance of Salmonella Typhimurium by Autophagy. *PLoS Pathog*. 2015; 11: e1005174. <https://doi.org/10.1371/journal.ppat.1005174> PMID: 26451915
 51. Dengjel J, Schoor O, Fischer R, Reich M, Kraus M, Müller M, et al. Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. *Proc Natl Acad Sci U S A*. 2005; 102: 7922–7927. <https://doi.org/10.1073/pnas.0501190102> PMID: 15894616

52. Levine B, Deretic V. Unveiling the roles of autophagy in innate and adaptive immunity. *Nat Rev Immunol*. 2007; 7: 767–777. <https://doi.org/10.1038/nri2161> PMID: 17767194
53. Paludan C, Schmid D, Landthaler M, Vockerodt M, Kube D, Tuschl T, et al. Endogenous MHC class II processing of a viral nuclear antigen after autophagy. *Science*. 2005; 307: 593–596. <https://doi.org/10.1126/science.1104904> PMID: 15591165
54. Lee HK, Mattei LM, Steinberg BE, Alberts P, Lee YH, Chervonsky A, et al. In vivo requirement for Atg5 in antigen presentation by dendritic cells. *Immunity*. 2010; 32: 227–239. <https://doi.org/10.1016/j.immuni.2009.12.006> PMID: 20171125
55. Saini NK, Baena A, Ng TW, Venkataswamy MM, Kennedy SC, Kunnath-Velayudhan S, et al. Suppression of autophagy and antigen presentation by Mycobacterium tuberculosis PE_PGRS47. *Nat Microbiol*. 2016; 1: 16133. <https://doi.org/10.1038/nmicrobiol.2016.133> PMID: 27562263
56. Moguche AO, Shafiani S, Clemons C, Larson RP, Dinh C, Higdon LE, et al. ICOS and Bcl6-dependent pathways maintain a CD4 T cell population with memory-like properties during tuberculosis. *J Exp Med*. 2015; 212: 715–728. <https://doi.org/10.1084/jem.20141518> PMID: 25918344
57. Rogerson BJ, Jung Y-J, LaCourse R, Ryan L, Enright N, North RJ. Expression levels of Mycobacterium tuberculosis antigen-encoding genes versus production levels of antigen-specific T cells during stationary level lung infection in mice. *Immunology*. 2006; 118: 195–201. <https://doi.org/10.1111/j.1365-2567.2006.02355.x> PMID: 16771854
58. Moguche AO, Musvosvi M, Penn-Nicholson A, Plumlee CR, Mearns H, Geldenhuys H, et al. Antigen Availability Shapes T Cell Differentiation and Function during Tuberculosis. *Cell Host Microbe*. 2017; 21: 695–706.e5. <https://doi.org/10.1016/j.chom.2017.05.012> PMID: 28618268
59. Sani M, Houben ENG, Geurtsen J, Pierson J, de Punder K, van Zon M, et al. Direct visualization by cryo-EM of the mycobacterial capsular layer: a labile structure containing ESX-1-secreted proteins. *PLoS Pathog*. 2010; 6: e1000794. <https://doi.org/10.1371/journal.ppat.1000794> PMID: 20221442
60. Daffé M. The cell envelope of tubercle bacilli. *Tuberculosis (Edinb)*. 2015;95 Suppl 1: S155-8. <https://doi.org/10.1016/j.tube.2015.02.024> PMID: 25819158
61. Beatty WL, Rhoades ER, Ullrich HJ, Chatterjee D, Heuser JE, Russell DG. Trafficking and release of mycobacterial lipids from infected macrophages. *Traffic*. 2000; 1: 235–247. <https://doi.org/10.1034/j.1600-0854.2000.010306.x> PMID: 11208107
62. Penn BH, Netter Z, Johnson JR, Von Dollen J, Jang GM, Johnson T, et al. An Mtb-Human Protein-Protein Interaction Map Identifies a Switch between Host Antiviral and Antibacterial Responses. *Mol Cell*. 2018; 71: 637–648.e5. <https://doi.org/10.1016/j.molcel.2018.07.010> PMID: 30118682
63. Sogi KM, Lien KA, Johnson JR, Krogan NJ, Stanley SA. The Tyrosine Kinase Inhibitor Gefitinib Restricts Mycobacterium tuberculosis Growth through Increased Lysosomal Biogenesis and Modulation of Cytokine Signaling. *ACS Infect Dis*. 2017; 3: 564–574. <https://doi.org/10.1021/acsinfecdis.7b00046> PMID: 28537707
64. Gonçalves A V, Margolis SR, Quirino GFS, Mascarenhas DPA, Rauch I, Nichols RD, et al. Gasdermin-D and Caspase-7 are the key Caspase-1/8 substrates downstream of the NAIP5/NLRC4 inflammasome required for restriction of Legionella pneumophila. *PLoS Pathog*. 2019; 15: e1007886. <https://doi.org/10.1371/journal.ppat.1007886> PMID: 31251782
65. Reniere ML, Whiteley AT, Portnoy DA. An In Vivo Selection Identifies Listeria monocytogenes Genes Required to Sense the Intracellular Environment and Activate Virulence Factor Expression. *PLoS Pathog*. 2016; 12: e1005741. <https://doi.org/10.1371/journal.ppat.1005741> PMID: 27414028
66. Coers J, Vance RE, Fontana MF, Dietrich WF. Restriction of Legionella pneumophila growth in macrophages requires the concerted action of cytokine and Naip5/lpaf signalling pathways. *Cell Microbiol*. 2007; 9: 2344–2357. <https://doi.org/10.1111/j.1462-5822.2007.00963.x> PMID: 17506816
67. Wang C, Mei L. In utero electroporation in mice. *Methods Mol Biol*. 2013; 1018: 151–163. https://doi.org/10.1007/978-1-62703-444-9_15 PMID: 23681626
68. Van Dis E, Sogi KM, Rae CS, Sivick KE, Surh NH, Leong ML, et al. STING-Activating Adjuvants Elicit a Th17 Immune Response and Protect against Mycobacterium tuberculosis Infection. *Cell Rep*. 2018; 23: 1435–1447. <https://doi.org/10.1016/j.celrep.2018.04.003> PMID: 29719256
69. Morrison H, Cox J, Penn B. Mass spectrometry data from: Deficiency in Galectin-3, -8, and -9 impairs immunity to chronic Mycobacterium tuberculosis infection but not acute infection with multiple intracellular pathogens. *Dryad*; 2022. <https://doi.org/10.6078/D1914X>